p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors - PubMed (original) (raw)
p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors
Mitsugu Yamamoto et al. Cancer Sci. 2014 Jan.
Abstract
Aromatase inhibitors have played a central role in endocrine therapy for estrogen receptor (ER)-positive breast cancer in postmenopausal women. However, factors predictive of the efficacy of aromatase inhibitors, and prognostic factors, both for early and late recurrence in women treated with adjuvant aromatase inhibitors have not been identified. Whole genome analysis identified that a TP53 gene mutation exists in ER-positive breast cancers, although the frequency of TP53 gene mutation in luminal tumors is lower compared with basal-like or human epidermal growth factor receptor type 2 (HER2)-positive breast cancers. We examined expression of p53, as well as ER, progesterone receptor, HER2 and Ki-67 using immunohistochemistry in postmenopausal ER-positive breast cancer patients who were treated with aromatase inhibitors as adjuvant endocrine therapy. There were 53 (21%) tumors that contained 10% or more p53-positive cells. High p53 expression was positively correlated with tumor grade, HER2 score and Ki-67 expression. Significant association was observed between disease-free survival and high p53 expression in multivariate analysis (P < 0.0001). Compared with women without recurrence, women with early recurrence had significantly higher p53 expression (P < 0.0001), as did women with late recurrence (P = 0.037). The present study demonstrates that p53 accumulation is a strong predictor of both early and late recurrence in ER-positive breast cancer patients treated with aromatase inhibitors as adjuvant endocrine therapy. TP53 gene alteration might be a key biological characteristic of ER-positive breast cancer.
Keywords: Aromatase inhibitor; breast cancer; endocrine therapy; p53; prognosis.
© 2013 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.
Figures
Figure 1
Immunohistochemical examination of Ki-67 (a) and p53 (b) in invasive carcinoma. Representative results of positive staining are shown. Nuclear staining of Ki-67 (a) and p53 (b) can be observed in breast cancer cells.
Figure 2
Immunohistochemical examination of p53 in various cancer cell lines using formalin-fixed, paraffin-embedded cell block materials. Representative results are shown. Negative or only weak staining in a few cells is observed in H1299 p53 null cells and in H2228, Lovo, Hela and MCF-7 cells that do not have the TP53 gene mutation (upper panel), whereas nuclear staining can be observed in all cells in T47D, SK-BR-3, BT-474, MDA-MB-231 and MDA-MB-468 cells that have missense mutations of the TP53 gene (lower panel).
Figure 3
Disease-free survival according to expression of Ki-67 (a), p53 (b) and combination subgroups of Ki-67 and p53 (c) in estrogen-positive breast cancer patients treated with aromatase inhibitors as adjuvant endocrine therapy.
Similar articles
- High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.
Endo Y, Toyama T, Takahashi S, Sugiura H, Yoshimoto N, Iwasa M, Kobayashi S, Fujii Y, Yamashita H. Endo Y, et al. Int J Clin Oncol. 2011 Oct;16(5):512-8. doi: 10.1007/s10147-011-0215-5. Epub 2011 Mar 23. Int J Clin Oncol. 2011. PMID: 21431343 - Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
Kurozumi S, Matsumoto H, Inoue K, Tozuka K, Hayashi Y, Kurosumi M, Oyama T, Fujii T, Horiguchi J, Kuwano H. Kurozumi S, et al. PLoS One. 2018 Aug 6;13(8):e0201846. doi: 10.1371/journal.pone.0201846. eCollection 2018. PLoS One. 2018. PMID: 30080878 Free PMC article. - Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T, Osako T, Takahashi M, Endo Y, Hosoda M, Ishida N, Horii R, Yamazaki K, Miyoshi Y, Yasojima H, Tomioka N; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Yamashita H, et al. Breast Cancer. 2016 Nov;23(6):830-843. doi: 10.1007/s12282-015-0649-0. Epub 2015 Oct 14. Breast Cancer. 2016. PMID: 26467036 - American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. Winer EP, et al. J Clin Oncol. 2005 Jan 20;23(3):619-29. doi: 10.1200/JCO.2005.09.121. Epub 2004 Nov 15. J Clin Oncol. 2005. PMID: 15545664 Review. - Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Bedard PL, Piccart-Gebhart MJ. Bedard PL, et al. Curr Opin Oncol. 2009 Nov;21(6):491-8. doi: 10.1097/CCO.0b013e32832fc8b0. Curr Opin Oncol. 2009. PMID: 19593135 Review.
Cited by
- Combined Gadolinium and Boron Neutron Capture Therapies for Eradication of Head-and-Neck Tumor Using Gd10B6 Nanoparticles under MRI/CT Image Guidance.
Shanmugam M, Kuthala N, Kong X, Chiang CS, Hwang KC. Shanmugam M, et al. JACS Au. 2023 Aug 4;3(8):2192-2205. doi: 10.1021/jacsau.3c00250. eCollection 2023 Aug 28. JACS Au. 2023. PMID: 37654578 Free PMC article. - Positive p53 Expression Is Associated with Primary Endocrine Therapy Resistance in Locally Advanced Stage Luminal B HER2-Negative Breast Cancer Patients: A Cross-Sectional Study in Indonesia.
Halim F, Azhar Y, Suwarman S, Wahjoepramono EJ, Hernowo B. Halim F, et al. Diagnostics (Basel). 2023 May 24;13(11):1838. doi: 10.3390/diagnostics13111838. Diagnostics (Basel). 2023. PMID: 37296690 Free PMC article. - ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
Chen JW, Jacot W, Cortés J, Krop IE, Dent S, Harbeck N, De Laurentiis M, Diéras V, Im YH, Stout TJ, Schimmoller F, Savage HM, Hutchinson KE, Wilson TR. Chen JW, et al. Mol Oncol. 2023 Oct;17(10):2000-2016. doi: 10.1002/1878-0261.13416. Epub 2023 Mar 25. Mol Oncol. 2023. PMID: 36892268 Free PMC article. - Endocrine resistance and breast cancer plasticity are controlled by CoREST.
Garcia-Martinez L, Adams AM, Chan HL, Nakata Y, Weich N, Stransky S, Zhang Z, Alshalalfa M, Sarria L, Mahal BA, Kesmodel SB, Celià-Terrassa T, Liu Z, Minucci S, Bilbao D, Sidoli S, Verdun RE, Morey L. Garcia-Martinez L, et al. Nat Struct Mol Biol. 2022 Nov;29(11):1122-1135. doi: 10.1038/s41594-022-00856-x. Epub 2022 Nov 7. Nat Struct Mol Biol. 2022. PMID: 36344844 Free PMC article. - Immunohistochemical Detection and Prognostic Significance of p53, Epidermal Growth Factor Receptor, Murine Double Minute 2, and Isocitrate Dehydrogenase 1 in Glioblastoma Multiforme Patients of Pakistan.
Ali SMA, Shamim MS, Enam SA, Ahmad Z, Adnan Y, Farooqui HA. Ali SMA, et al. Clin Med Insights Oncol. 2022 Aug 22;16:11795549221119107. doi: 10.1177/11795549221119107. eCollection 2022. Clin Med Insights Oncol. 2022. PMID: 36035640 Free PMC article.
References
- Iwase H. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer. 2008;15:278–90. - PubMed
- Cardoso F, Senkus-Konefka E, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v15–9. - PubMed
- Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28:1829–34. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous